
Anika Therapeutics Inc
Health Care · USD
Price
$14.76
Cap
$198M
Earnings
3/4 beat
30d Trend
-3%
Near 52-week highs — limited upside before resistance
Target range: $17 – $18 (consensus: $17.5)
Consensus: Moderate Buy
Earnings history
Q4 2025
BEAT
0.31 vs 0.02
Q3 2025
MISS
-0.22 vs
Q2 2025
BEAT
0.31 vs
Q1 2025
BEAT
0.12 vs
Key macro factors
Global economic challenges affecting healthcare spending and consumer discretionary income for elective procedures and treatments.
Inflation and supply chain pressures impacting manufacturing, raw material (e.g., hyaluronic acid), and distribution costs for medical devices and therapeutics.
Evolving healthcare policies, insurance coverage, and reimbursement rates for orthopedic and pain management solutions, which can directly influence product demand and revenue.
Anika Therapeutics, Inc. is a global joint preservation company focused on early intervention orthopedic care, specializing in osteoarthritis (OA) pain management and regenerative solutions based on hyaluronic acid and implant technologies.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.
